ALK and non-small cell lung carcinoma: [63], 14% of NSCLC patients with both ALK and TP53 mutations have MYC amplification, which lead to EML4‐ALK upregulation and suggest a potential MYC‐dependent mechanism for ALK‐TKIs resistance.